4.6 Review

Virtual and Augmented Reality in Cardiovascular Care State-of-the-Art and Future Perspectives

Journal

JACC-CARDIOVASCULAR IMAGING
Volume 15, Issue 3, Pages 519-532

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jcmg.2021.08.017

Keywords

augmented reality; cardiovascular care; imaging; virtual reality

Funding

  1. Abbott
  2. Edwards
  3. Daiichi Sankyo
  4. Boehringer Ingelheim
  5. CSL Behring
  6. Ferring Pharmaceuticals
  7. Bayer
  8. Afimmune
  9. Amarin
  10. Amgen
  11. AstraZeneca
  12. Bristol-Myers Squibb
  13. Cardax
  14. Chiesi
  15. Eisai
  16. Ethicon
  17. Forest Laboratories
  18. Fractyl
  19. Idorsia
  20. Ironwood
  21. Ischemix
  22. Lexicon
  23. Lilly
  24. Medtronic
  25. Pfizer
  26. PhaseBio
  27. PLx Pharma
  28. Regeneron
  29. Roche
  30. Sanofi Aventis
  31. Synaptic
  32. Medicines Company
  33. AliveCor

Ask authors/readers for more resources

Virtual reality and augmented reality have wide applications in cardiovascular education and treatment, with potential in various fields. However, there are technical challenges to overcome and ethical considerations to address, while ensuring the focus of physicians and patients.
Applications of virtual reality (VR) and augmented reality (AR) assist both health care providers and patients in cardiovascular education, complementing traditional learning methods. Interventionalists have successfully used VR to plan difficult procedures and AR to facilitate complex interventions. VR/AR has already been used to treat patients, during interventions in rehabilitation programs and in immobilized intensive care patients. There are numerous additional potential applications in the catheterization Laboratory. By using AR, interventionalists could combine visual fluoroscopy information projected and registered on the patient body with data derived from preprocedural imaging and live fusion of different imaging modalities such as fluoroscopy with echocardiography. Persistent technical challenges to overcome include the integration of different imaging modalities into VR/AR and the harmonization of data flow and interfaces. Cybersickness might exclude some patients and users from the potential benefits of VR/AR. Critical ethical considerations arise in the application of VR/AR in vulnerable patients. In addition, digital applications must not distract physicians from the patient. It is our duty as physicians to participate in the development of these innovations to ensure a virtual health reality benefit for our patients in a real-world setting. The purpose of this review is to summarize the current and future role of VR and AR in different fields within cardiology, its challenges, and perspectives. (C) 2022 by the American College of Cardiology Foundation.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available